# Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors

> **NCT00085878** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Solid Tumor Cancer

## Interventions

- **DRUG:** SB-485232

## Key facts

- **NCT ID:** NCT00085878
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2008-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085878, "Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00085878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*